N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A

FEBS Journal

Volumn 280, Issue 23, 2013, Pages 6223-6232

  Bifulco, Maurizio ^a   D'Alessandro, Alba ^a   Paladino, Simona ^b   Malfitano, Anna M ^a   Notarnicola, Maria ^c   Caruso, Maria G ^c   Laezza, Chiara ^d  

^a UNIVERSITY OF SALERNO   (Italy)

^b Dipartimento di Medicina Molecolare e Biotecnologie Mediche   (Italy)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^d CNR   (Italy)

Author keywords

farnesyl diphosphate synthase; Hutchinson Gilford progeria syndrome; mevalonate pathway; N6 isopentenyladenosine; prelamin A

Indexed keywords

6 N (3,3 DIMETHYLALLYL)ADENOSINE; FARNESYL TRANS TRANSFERASE; LAMIN; MEVINOLIN; RAS PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; PRENYLATION; PRIORITY JOURNAL; PROGERIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

FARNESYL DIPHOSPHATE SYNTHASE; HUTCHINSON-GILFORD PROGERIA SYNDROME; MEVALONATE PATHWAY; N6-ISOPENTENYLADENOSINE; PRELAMIN A;

ADOLESCENT; ADULT; BLOTTING, WESTERN; CELL NUCLEUS; CELLS, CULTURED; CHILD; FIBROBLASTS; GERANYLTRANSTRANSFERASE; HUMANS; IMMUNOPRECIPITATION; ISOPENTENYLADENOSINE; MALE; MICROSCOPY, FLUORESCENCE; NUCLEAR PROTEINS; PLANT GROWTH REGULATORS; PROGERIA; PROTEIN PRECURSORS; PROTEIN PRENYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84888290512     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12544     Document Type: Article

References (31)

1. Cao H, &, Hegele RA, (2003) LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J Hum Genet 48, 271-274.
2. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, et al,. (2003) Lamin A truncation in Hutchinson-Gilford progeria. Science 300, 2055.
3. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, et al,. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293-298.
4. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, et al,. (2004) Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 101, 8963-8968.
5. McClintock D, Gordon LD, &, Djabali K, (2006) Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-lamin A G608G antibody. Proc Natl Acad Sci USA 103, 2154-2159.
6. Shumaker DK, Dechat T, Kohlmaier A, Adam SA, Bozovsky MR, Erdos MR, Eriksson M, Goldman AE, Khuon S, Collins FS, et al,. (2006) Mutant lamin A leads to progressive alterations of epigenic control in premature aging. Proc Natl Acad Sci USA 103, 8703-8708.
7. Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang JD, Li KM, Chau PY, Chen DJ, et al,. (2005) Genomic instability in laminopathy-based premature aging. Nat Med 11, 780-785.
8. Reddy S, &, Comai L, (2012) Lamin A, farnesylation and aging. Exp Cell Res 318, 1-7.
9. Coutinho HD, Falcao-Silva VS, Goncalves GF, &, da Nobrega RB, (2009) Molecular ageing in progeroid syndromes: Hutchinson-Gilford progeria syndrome as a model. Immun Ageing 6, 1-7.
10. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, et al,. (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358, 592-604.
11. Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, Moulson CL, Miner JH, Young SG, &, Fong LG, (2005) Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci USA 102, 12873-12878.
12. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, &, Collins FS, (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 102, 12879-12884.
13. Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, &, Young SG, (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311, 1621-1623.
14. Varela I, Pereira S, Ugalde AP, Navarro CL, Suárez MF, Cau P, Cadiñanos J, Osorio FG, Foray N, Cobo J, et al,. (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 14, 767-772.
15. Young SG, Yang SH, Davies BSJ, Jung HJ, &, Fong LG, (2013) Targeting protein prenylation in progeria. Sci Transl Med 5, 171.
16. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, et al,. (2012) Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 109, 16666-16671.
17. Gordon LB, Cao K, &, Collins FS, (2013) Progeria: translational insights from cell biology. J Cell Biol 199, 9-13.
18. Bifulco M, Malfitano AM, Proto MC, Santoro A, Caruso MG, &, Laezza C, (2008) Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug. Anticancer Agents Med Chem 8, 200-204.
19. Laezza C, Caruso MG, Gentile T, Notarnicola M, Malfitano AM, Di Matola T, Messa C, Gazzerro P, &, Bifulco M, (2009) N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1. Int J Cancer 124, 1322-1329.
20. Laezza C, Malfitano AM, Di Matola T, Ricchi P, &, Bifulco M, (2010) Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells. Mol Carcinog 49, 892-901.
21. Laezza C, Notarnicola M, Caruso MG, Messa C, Macchia M, Bertini S, Minutolo F, Portella G, Fiorentino L, Stingo S, et al,. (2006) N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB J 20, 412-418.
22. Goldstein JL, &, Brown MS, (1990) Regulation of the mevalonate pathway. Nature 34, 425-430.
23. Dhar MK, Koul A, &, Kaul S, (2013) Farnesyl pyrophosphate synthase: a key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development. N Biotechnol 30, 114-123.
24. Laezza C, Di Marzo V, &, Bifulco M, (1998) v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. Proc Natl Acad Sci USA 95, 13646-13651.
25. Sinensky M, Fantlc K, Trujillo MA, McLain TM, Kupfer A, &, Dalton M, (1994) The processing pathway of prelamin A. J Cell Sci 7, 61-67.
26. Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, Meta M, Bendale P, Gelb MH, Young SG, et al,. (2005) Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA 102, 10291-10296.
27. Dahl KN, Scaffidi P, Islam MF, Yodh AG, Wilson KL, &, Misteli T, (2006) Distinct structural and mechanical properties of the nuclear lamina in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 103, 10271-10276.
28. Scaffidi P, &, Misteli T, (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11, 440-445.
29. Krisans SK, Ericsson J, Edwards PA, &, Keller GA, (1994) Farnesyl-diphosphate synthase is localized in peroxisomes. J Biol Chem 269, 14165-14169.
30. Gupta SD, Mehan RS, Tansey TR, Chen HT, Goping G, Goldberg I, &, Shechter I, (1999) Differential binding of proteins to peroxisomes in rat hepatoma cells: unique association of enzymes involved in isoprenoid metabolism. J Lipid Res 40, 1572-1584.
31. Livak KJ, &, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25, 402-408.